Oğuz Dursun

Prof. Dr. Oğuz Dursun

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in American Journal of Infection Control
Verified
Journal Article
Closed access
VRVíctor Daniel Rosenthal
Víctor Daniel Rosenthal
DMDennis George Maki
Dennis George Maki
YMYatin Mehta
Yatin Mehta
HLHakan Leblebicioglu
Hakan Leblebicioglu
ZMZiad Ahmed Memish
Ziad Ahmed Memish
DADinh Pham Phuong Anh
Dinh Pham Phuong Anh

19 March 2012 in Critical Care
Verified
Journal Article
Open access
PDF file
DDDemet Demirkol
Demet Demirkol
DYDincer Yildizdas
Dincer Yildizdas
BBBenan Bayrakci
Benan Bayrakci
BKBulent Karapinar
Bulent Karapinar
TKTANIL KENDIRLI
TANIL KENDIRLI
TGTurkish Secondary HLH/MAS Critical Care Study Group
Turkish Secondary HLH/MAS Critical Care Study Group
Introduction: Hyperferritinemia is associated with increased mortality in pediatric sepsis, multiple organ dysfunction syndrome (MODS), and critical illness. The International Histiocyte Society has recommended that children with hyperferritinemia and secondary hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) should be treated with the same immunosuppressant/cytotoxic therapies used to treat primary HLH. We hypothesized that patients with hyperferritinemia associated secondary HLH/sepsis/MODS/MAS can be successfully treated with a less immunosuppressant approach than is recommended for primary HLH. Methods: We conducted a multi-center cohort study of children in Turkish Pediatric Intensive Care units with hyperferritinemia associated secondary HLH/sepsis/MODS/MAS treated with less immunosuppression (plasma exchange and intravenous immunoglobulin or methyl prednisolone) or with the primary HLH protocol (plasma exchange and dexamethasone or cyclosporine A and/or etoposide). The primary outcome assessed was hospital survival. Results: Twenty-three children with hyperferritinemia and secondary HLH/sepsis/MODS/MAS were enrolled (median ferritin = 6341 μg/dL, median number of organ failures = 5). Univariate and multivariate analyses demonstrated that use of plasma exchange and methyl prednisolone or intravenous immunoglobulin (n = 17, survival 100%) was associated with improved survival compared to plasma exchange and dexamethasone and/or cyclosporine and/or etoposide (n = 6, survival 50%) (P = 0.002). Conclusions: Children with hyperferritinemia and secondary HLH/sepsis/MODS/MAS can be successfully treated with plasma exchange, intravenous immunoglobulin, and methylprednisone. Randomized trials are required to evaluate if the HLH-94 protocol is helpful or harmful compared to this less immune suppressive and cytotoxic approach in this specific population.

28 February 2012 in Infection
Verified
Journal Article
Closed access
PDF file
VRV. D. Rosenthal
V. D. Rosenthal
BRB. Ramachandran
B. Ramachandran
WVW. Villamil-Gómez
W. Villamil-Gómez
AAA. Armas-Ruiz
A. Armas-Ruiz
JNJ. A. Navoa-Ng
J. A. Navoa-Ng
ODOğuz Dursun
Oğuz Dursun

1 August 2012 in American Journal of Infection Control
Verified
Journal Article
Closed access
VRVictor D. Rosenthal
Victor D. Rosenthal
CACarlos Alvarez-Moreno
Carlos Alvarez-Moreno
WVWilmer Villamil-Gómez
Wilmer Villamil-Gómez
SSSanjeev Singh
Sanjeev Singh
BRBala Ramachandran
Bala Ramachandran
NKNecdet Kuyucu
Necdet Kuyucu

1 July 2009 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
ODOğuz Dursun
Oğuz Dursun
VHVolkan Hazar
Volkan Hazar
GKGulsun Tezcan Karasu
Gulsun Tezcan Karasu
VUVedat Uygun
Vedat Uygun
OTOzgur Tosun
Ozgur Tosun
AYAkif Yesilipek
Akif Yesilipek
Higher mortality and morbidity are well established in children with malignancies in whom intensive care admissions are required. A retrospective cohort study was conducted to assess the risk factors for children with cancer in the pediatric intensive care unit (PICU) for short-term outcome (survival vs. nonsurvival when leaving the PICU). The records of 36 children with a median age of 5 years (range: 0.5 to 21) between August 2004 and August 2007 were reviewed. Mortality rate was 55%, higher than the yearly overall PICU mortality rate of 12% (P10 points) and low (≤10 points) PRISM III score, respectively (P=0.05). Mortality rate was significantly related to presence and number of organ system dysfunction (P=0.031 and P=0.013, respectively), sepsis (P=0.05), mechanical ventilation (P=0.005), and positive inotropic support (P=0.003). By using multiple logistic regressions, the independent risk factor was PRISM III score at the time of admission to PICU (P=0.05). The PRISM III score performed well as a predictor of outcome. For decision to admit such patients to the PICU or to forgo life-sustaining therapies, other factors such as need for mechanical ventilation and positive inotropic support, presence and numbers of organ system dysfunction should be taken into consideration as well.

1 October 2013 in American Journal of Infection Control
Verified
Journal Article
Closed access
HLHakan Leblebicioglu
Hakan Leblebicioglu
GEGulden Ersoz
Gulden Ersoz
VRVictor Daniel Rosenthal
Victor Daniel Rosenthal
ANAta Nevzat-Yalcin
Ata Nevzat-Yalcin
ÖAÖzay Arıkan Akan
Özay Arıkan Akan
FBFeza Bacakoglu
Feza Bacakoglu